Independence Bank of Kentucky Buys 185 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Independence Bank of Kentucky boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 83.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 406 shares of the medical research company’s stock after acquiring an additional 185 shares during the period. Independence Bank of Kentucky’s holdings in IQVIA were worth $80,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth $27,000. Park Place Capital Corp bought a new stake in IQVIA during the third quarter valued at $28,000. Synergy Asset Management LLC bought a new position in shares of IQVIA in the 4th quarter worth about $33,000. Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Finally, Assetmark Inc. boosted its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on IQV shares. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. The Goldman Sachs Group cut their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Stephens started coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Finally, Morgan Stanley reduced their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Price Performance

Shares of NYSE:IQV opened at $201.34 on Monday. The company has a 50-day moving average price of $200.41 and a two-hundred day moving average price of $220.39. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $36.54 billion, a PE ratio of 26.42, a P/E/G ratio of 2.12 and a beta of 1.48.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.